Pharmaceutical Technology

FEBRUARY 8, 2024

In recognition of its 30th anniversary, the International Gaucher Alliance (IGA) unveiled a visionary five-year strategic plan extending to 2029.

52

52

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Hepatocellular Carcinoma.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Colorectal Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Bladder Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Solid Tumor.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Thymoma (Thymic Epithelial Tumor).

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Kidney Cancer (Renal Cell Cancer).

40

40

Express Pharma

SEPTEMBER 4, 2023

SB5 is set to become a leading biosimilar for this debilitating, chronic condition, with a global sales forecast of $832 million by 2029, according to GlobalData. The post Humira biosimilar to see $832 million in sales by 2029: GlobalData appeared first on Express Pharma.

Biosimilars 52

Biosimilars 52

Express Pharma

MARCH 15, 2024

per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029. per cent CAGR and a market size of $51 billion in 2029, nearly half of the GLP1 agonist market. billion annually by 2029.

Diabetes 98

Diabetes Compounding 98

STAT

OCTOBER 31, 2023

Later, Amgen reworked old patent applications and, by doing so, succeeded in extending patent protection for the medicine from 2019 until 2029, according to an analysis by the advocacy group. Continue to STAT+ to read the full story…

Drug Pricing 282

Drug Pricing 282

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement 80

Process Improvement Biosimilars Drug Development 80

Pharmaceutical Technology

SEPTEMBER 22, 2023

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

59

59

Pharmaceutical Technology

JULY 31, 2023

According to GlobalData, it is projected that the market for hepatitis B treatments will experience a sharp increase over the next six years.

52

52

Pharmaceutical Commerce

JANUARY 5, 2024

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

OCTOBER 23, 2023

The Remicade biosimilar is forecasted to have sales of $2.3bn by 2029 as a subcutaneous form is approved for the US market.

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

AUGUST 31, 2023

Daiichi Sankyo and AstraZeneca’s blockbuster anti-cancer drug Enhertu could become a pan-tumour drug, with projected sales of $9.9bn by 2029.

52

52

Pharmaceutical Technology

NOVEMBER 1, 2023

The Amgen biosimilar Wezlana has been approved for all indications and is forecasted to yield $455m in 2029.

Biosimilars 52

Biosimilars 52

Express Pharma

AUGUST 31, 2023

The global market for mRNA-based oncology therapies is expected to reach a record-breaking $2 billion by 2029. per cent share by 2029, according to GlobalData. per cent of the total mRNA therapy market by 2029. BioNTech, a German pharma company, is expected to lead the market with projected sales of $885 million and a 44.6

Immunity 100

Immunity Immunization Vaccines 100

Express Pharma

FEBRUARY 5, 2024

GlobalData analyst consensus forecast predicts that tarlatamab will rake in $781 million by 2029 and will establish itself as a market leader for SCLC treatment. Globaldata analyst consensus forecast predicts HPN-217 and -328 to reach global sales of $161 and $192 million, respectively, by 2029. “

Compounding 98

Compounding Drug Development 98

Express Pharma

NOVEMBER 16, 2023

The global cell and gene therapy market is expected to reach $80 billion in 2029, with a high compound annual growth rate of 51.6 per cent between 2023 and 2029, according to GlobalData forecasts. The US FDA is currently considering approval of Casgevy for SCA. The limiting factor for widespread usage of this drug is its high cost.

Compounding 59

Compounding 59

Express Pharma

DECEMBER 28, 2023

According to GlobalData estimates, the global CGT market is projected to reach $80 billion by 2029. Oncology is expected to continue its lead as the indication and area of major development for cell and gene therapies, accounting for 44 per cent of the CGT market by 2029.

Drug Development 93

Drug Development 93

Express Pharma

NOVEMBER 12, 2023

million cases in 2029, equating to an annual growth rate of 6.46 million cases in 2029, equating to an annual growth rate of 2.71 According to GlobalData’s Pharmaceutical Intelligence Center, the diagnosed prevalent cases of NASH in India are projected to increase from 10.7 million cases in 2023 to 12.6 million cases in 2023 to 6.5

Diabetes 96

Diabetes 96

Pharmaceutical Technology

JULY 20, 2023

By 2029, RSV drugs are forecast to surpass $9bn in sales, This surge can be attributed to recent developments in preventative measures.

40

40

Express Pharma

NOVEMBER 7, 2023

billion in 2022, whereas Mounjaro, which received approval in 2022, is forecast to overtake this, generating over $27 billion in 2029 alone. Cagrisema is forecast to be a blockbuster, generating nearly $8 billion in revenue in 2029. Ozempic generated global sales of $8.5

Diabetes 99

Diabetes 99

Express Pharma

SEPTEMBER 19, 2023

billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 The high prevalence of breast cancer, ovarian cancer, pancreatic cancer and cancers of the lung and intestine is a key driver of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to reach $536.01 per cent from 2021 to 2030.

Chemotherapy 100

Chemotherapy Compounding 100

Express Pharma

JULY 4, 2023

The latest deals will see the biotech division of the Samsung Group produce biosimilar products ranging from oncology and inflammation to immunotherapy in the period to 2029 at its new Plant 4 in South Korea. The latest orders bring this year’s combined tally of orders from Pfizer to $1.08 billion, Samsung Biologics said in a statement.

Biosimilars 90

Biosimilars 90

Pharmaceutical Technology

APRIL 28, 2023

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Diabetes 52

Diabetes Dosage Compounding Labelling 52

Express Pharma

OCTOBER 10, 2023

GlobalData’s latest report “ Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2029 ,” reveals that in the 8MM (US, 5EU, Japan, and Australia), the number of individuals affected by RA is projected to rise from 6,308,268 cases in 2019 to 6,980,823 cases by 2029, with an annual growth rate (AGR) of 1.07

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

SEPTEMBER 23, 2022

It is expected to expire on 21 January 2029, with paediatric exclusivity lasting until 21 July 2029. It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Merck’s second patent covers the co-formulation of sitagliptin and metformin present in Janumet.

Vaccines 69

Vaccines 69

European Pharmaceutical Review

FEBRUARY 21, 2024

Research predicts 2029 small molecule oncology market leaders The post EGFR inhibitor could provide major advance in lung cancer appeared first on European Pharmaceutical Review. Results from a Phase III trial in the neoadjuvant setting are expected later in 2024.

Chemotherapy 86

Chemotherapy 86

Pharmaceutical Technology

MAY 12, 2023

GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). GlobalData analysts predict the total revenue to be generated from currently marketed Seagen ADCs to be roughly $30bn through 2029. targeting ADC.

Chemotherapy 64

Chemotherapy Compounding 64

European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Once equipped, the facility is expected to create a total of 800 jobs: 700 jobs in the new API facility and 100 jobs in the new packaging facility.

Packaging 95

Packaging Pharmaceutical Manufacturing Diabetes 95

Express Pharma

SEPTEMBER 5, 2023

billion in 2029. There are a few strategies that have been shown to lower Lp(a) levels, including niacin, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, antisense oligonucleotides, and lifestyle modifications. GlobalData forecasts olpasiran sales to reach $1.05

98

98

European Pharmaceutical Review

FEBRUARY 5, 2024

Research predicts 2029 small molecule oncology market leaders A “big step forward” for biotech innovation In a similar move, legislation to restore immediate R&D expensing was passed in the US House of Representatives on 31 January 2024.

Drug Pricing 77

Drug Pricing 77

Pharmaceutical Technology

APRIL 24, 2023

billion in 2029, while Calquence is expected to make $5.31 billion in 2029. According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98 billion in the same year. While Imbruvica sales were $3.78 GlobalData is the parent company of Pharmaceutical Technology.

52

52

Pharmaceutical Technology

MAY 10, 2023

billion in global sales in 2029, while Truvada estimates amount to $30 million. Truvada has since gone generic, with Teva Pharmaceuticals launching the first FDA-approved Truvada generic in October 2020. According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Descovy is estimated to yield $1.83

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies 105